0

Incidence of a Subclinical Fascioliasis on Antipyrine Clearance and Metabolite Excretion in Sheep

A E Tufenkji, M Alvinerie, T Pineau, C Boulard, P Galtier

Xenobiotica. 1988 Apr;18(4):357-64.

PMID: 3400265

Abstract:

1. The pharmacokinetics of i.v. antipyrine (25 mg/kg) used as a model compound, were determined in young male sheep, before and each month after an oral infestation by 150 metacercariae of Fasciola hepatica, and 8 weeks following a flukicidal treatment. 2. The parasitic pathology was ascertained by the clinical observation of animals and the increase in plasma antibodies directed against liver flukes. 3. A significant decrease in the total plasma clearance of the drug occurred by week 4 to 16, and a 1.7 fold increase in mean residence time occurred by week 12 post-infection. 4. Urinary excretion of antipyrine metabolites was determined before and 8 weeks following the infestation. 4-Hydroxyantipyrine was the major urinary metabolite and its excretion was decreased by 30% in infected sheep, whereas there was no change in the excretion of norantipyrine, 3-hydroxymethylantipyrine or unmetabolized drug. 5. It is concluded that the impairment of antipyrine clearance in the course of fascioliasis could be related to the decrease in liver microsomal cytochrome P-450-dependent mono-oxygenases observed in sheep with a similar parasitic burden.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP89258 Antipyrine Related Compound A Antipyrine Related Compound A 89-25-8 Price
qrcode